Aratana Therapeutics, Inc. (PETX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.30 / 7.16
Exchange NASDAQ
Div & Yield N.A. (N.A)
First Week Of February 2020 Options Trading For Aratana Therapeutics (PETX)

First Week Of February 2020 Options Trading For Aratana Therapeutics (PETX)

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the February 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 219 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Aratana Therapeutics' Stockholders Adopt Merger Agreement With Elanco Animal Health

Aratana Therapeutics' Stockholders Adopt Merger Agreement With Elanco Animal Health

Aratana Reports Voting Results from 2019 Special Meeting of Stockholders

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Aratana Therapeutics Granted FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension) 10 ML Vial

Aratana Therapeutics Granted FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension) 10 ML Vial

Commercial availability of NOCITA 10 mL vial size anticipated by fall 2019

Aratana Therapeutics Reports Voting Results From 2019 Annual Meeting Of Stockholders

Aratana Therapeutics Reports Voting Results From 2019 Annual Meeting Of Stockholders

Stockholders Elect All Class III Directors and Approve Proposals

Lifshitz & Miller LLP Announces Investigation Of Aratana Therapeutics, Inc., Community Health Systems, Equity Bancshares, Inc., Ford Motor Company, Interface, Inc., Monotype Imaging Holdings, Inc., PetIQ, Inc., And Pinduoduo, Inc.

Lifshitz & Miller LLP Announces Investigation Of Aratana Therapeutics, Inc., Community Health Systems, Equity Bancshares, Inc., Ford Motor Company, Interface, Inc., Monotype Imaging Holdings, Inc., PetIQ, Inc., And Pinduoduo, Inc.

NEW YORK, May 13, 2019 /PRNewswire/ --  Aratana Therapeutics, Inc. (PETX) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed merger of PETX with Elanco Animal Health for 0.

Aratana Therapeutics Reports First Quarter 2019 Financial Results

Aratana Therapeutics Reports First Quarter 2019 Financial Results

Continued revenue growth across portfolio of marketed pet therapeutics

Aratana Therapeutics To Present At Stifel 2019 Dental & Veterinary Conference

Aratana Therapeutics To Present At Stifel 2019 Dental & Veterinary Conference

LEAWOOD, Kan., May 7, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc.

INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Announced Buyout

INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Announced Buyout

NEW YORK, May 3, 2019 /PRNewswire/ --  Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Advanced Disposal Services, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Aratana Therapeutics, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Aratana Therapeutics, Inc.

NEW YORK, April 26, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Aratana Therapeutics, Inc.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Elanco Announces Agreement To Acquire Aratana Therapeutics; Completes Oncology Development Agreement With VetDC, Creates Specialty Veterinary Business Focus

Elanco Announces Agreement To Acquire Aratana Therapeutics; Completes Oncology Development Agreement With VetDC, Creates Specialty Veterinary Business Focus

Elanco Animal Health (NYSE:ELAN) today announced it has signed an agreement to acquire Aratana Therapeutics (NASDAQ:PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the...

Aratana Therapeutics To Be Acquired By Elanco Animal Health

Aratana Therapeutics To Be Acquired By Elanco Animal Health

Elanco announces formation of commercial team dedicated to veterinary specialty business

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BEP, CLFD, HOLX, LNTH, RLGT, THR, TWNK, YY Downgrades: AGI, DPLO, OCSI, PETX, SLCA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Interesting PETX Call Options For March 15th

Interesting PETX Call Options For March 15th

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PETX options chain for the new March 15th contracts and identified the following call contract of particular interest.

Noteworthy Friday Option Activity: PETX, HRI, PTE

Noteworthy Friday Option Activity: PETX, HRI, PTE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Aratana Therapeutics, Inc , where a total of 2,272 contracts have traded so far, representing approximately 227,200 underlying shares. That amounts to about 54% of PETX's average daily trading volume over the past month of 420,960 shares.

Aratana Therapeutics Becomes Oversold (PETX)

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTB, FII, GVA, MIME, PETX Downgrades: DF, FGEN, MUX, NXGN, PANL, TAIT Initiations: DESP Read on to get TheStreet Quant Ratings' detailed report:

Small Biotechs Finally Join in Market Rebound

Small Biotechs Finally Join in Market Rebound

Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.

First Week Of May 2019 Options Trading For Aratana Therapeutics (PETX)

First Week Of May 2019 Options Trading For Aratana Therapeutics (PETX)

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 210 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

3 Great Stocks to Buy If You Love Your Pet

3 Great Stocks to Buy If You Love Your Pet

The animal health market continues to be strong, and so is the outlook. Here are several plays on the space and why you should make them.

RSI Alert: Aratana Therapeutics (PETX) Now Oversold

RSI Alert: Aratana Therapeutics (PETX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Activist Fund Engaged Takes New Position in Cross Country Health

Activist Fund Engaged Takes New Position in Cross Country Health

Glenn Welling took a couple new stakes and maintained large stakes at key targets including Rent-A-Center, Hain Celestial and TiVo.

Oversold Conditions For Aratana Therapeutics (PETX)

Oversold Conditions For Aratana Therapeutics (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aratana Therapeutics Becomes Oversold (PETX)

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

Sector M&A activity is likely to pick up next year benefiting the space.

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.